Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 37

1.

Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma.

Saba NS, Liu D, Herman SE, Underbayev C, Tian X, Behrend D, Weniger MA, Skarzynski M, Gyamfi J, Fontan L, Melnick A, Grant C, Roschewski M, Navarro A, Beà S, Pittaluga S, Dunleavy K, Wilson WH, Wiestner A.

Blood. 2016 Jul 7;128(1):82-92. doi: 10.1182/blood-2015-11-681460.

PMID:
27127301
2.

The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?

Dreyling M, Ferrero S; European Mantle Cell Lymphoma Network..

Haematologica. 2016 Feb;101(2):104-14. doi: 10.3324/haematol.2014.119115. Review.

3.

Idelalisib for the treatment of non-Hodgkin lymphoma.

Graf SA, Gopal AK.

Expert Opin Pharmacother. 2016;17(2):265-74. doi: 10.1517/14656566.2016.1135130. Review.

PMID:
26818003
4.

Bortezomib in mantle cell lymphoma: comparative therapeutic outcomes.

Vallumsetla N, Paludo J, Kapoor P.

Ther Clin Risk Manag. 2015 Nov 6;11:1663-74. doi: 10.2147/TCRM.S72943. Review.

5.

Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma.

Ruan J, Martin P, Shah B, Schuster SJ, Smith SM, Furman RR, Christos P, Rodriguez A, Svoboda J, Lewis J, Katz O, Coleman M, Leonard JP.

N Engl J Med. 2015 Nov 5;373(19):1835-44. doi: 10.1056/NEJMoa1505237.

6.

Personalized medicine in lymphoma: is it worthwhile? The mantle cell lymphoma experience.

Dreyling M, Ferrero S; European Mantle Cell Lymphoma Network..

Haematologica. 2015 Jun;100(6):706-8. doi: 10.3324/haematol.2015.127472. No abstract available.

7.

The utility of mRNA analysis in defining SOX11 expression levels in mantle cell lymphoma and reactive lymph nodes.

Lord M, Wasik AM, Christensson B, Sander B.

Haematologica. 2015 Sep;100(9):e369-72. doi: 10.3324/haematol.2015.123885. No abstract available.

8.

Mantle cell lymphoma: observation to transplantation.

Rajabi B, Sweetenham JW.

Ther Adv Hematol. 2015 Feb;6(1):37-48. doi: 10.1177/2040620714561579. Review.

9.

A rare presentation of in situ mantle cell lymphoma and follicular lymphoma: a case report and review of the literature.

Taverna J, Nair A, Yun S, Paulson S, Schatz JH, Persky D, Fuchs D, Puvvada S.

Case Rep Hematol. 2014;2014:145129. doi: 10.1155/2014/145129.

10.

Non-Hodgkin's lymphomas, version 4.2014.

Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Czuczman MS, Fayad LE, Fisher RI, Glenn MJ, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Saad AA, Sokol L, Swinnen LJ, Tsien C, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H; National comprehensive cancer network..

J Natl Compr Canc Netw. 2014 Sep;12(9):1282-303.

11.

How to treat old MCL patients: one size fits it all?

Dreyling M, Ferrero S; European Mantle Cell Lymphoma Network..

Blood. 2014 Aug 21;124(8):1207-8. doi: 10.1182/blood-2014-06-578872. No abstract available.

12.

Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501).

Morrison VA, Jung SH, Johnson J, LaCasce A, Blum KA, Bartlett NL, Pitcher BN, Cheson BD.

Leuk Lymphoma. 2015 Apr;56(4):958-64. doi: 10.3109/10428194.2014.938333.

13.

Distinction between asymptomatic monoclonal B-cell lymphocytosis with cyclin D1 overexpression and mantle cell lymphoma: from molecular profiling to flow cytometry.

Espinet B, Ferrer A, Bellosillo B, Nonell L, Salar A, Fernández-Rodríguez C, Puigdecanet E, Gimeno J, Garcia-Garcia M, Vela MC, Luño E, Collado R, Navarro JT, de la Banda E, Abrisqueta P, Arenillas L, Serrano C, Lloreta J, Miñana B, Cerutti A, Florensa L, Orfao A, Sanz F, Solé F, Dominguez-Sola D, Serrano S.

Clin Cancer Res. 2014 Feb 15;20(4):1007-19. doi: 10.1158/1078-0432.CCR-13-1077.

14.

Tackling mantle cell lymphoma (MCL): Potential benefit of allogeneic stem cell transplantation.

Shanbhag S, Smith MR, Emmons RV.

Stem Cells Cloning. 2010 Jul 7;3:93-102. Review.

15.

Landscape of somatic mutations and clonal evolution in mantle cell lymphoma.

Beà S, Valdés-Mas R, Navarro A, Salaverria I, Martín-Garcia D, Jares P, Giné E, Pinyol M, Royo C, Nadeu F, Conde L, Juan M, Clot G, Vizán P, Di Croce L, Puente DA, López-Guerra M, Moros A, Roue G, Aymerich M, Villamor N, Colomo L, Martínez A, Valera A, Martín-Subero JI, Amador V, Hernández L, Rozman M, Enjuanes A, Forcada P, Muntañola A, Hartmann EM, Calasanz MJ, Rosenwald A, Ott G, Hernández-Rivas JM, Klapper W, Siebert R, Wiestner A, Wilson WH, Colomer D, López-Guillermo A, López-Otín C, Puente XS, Campo E.

Proc Natl Acad Sci U S A. 2013 Nov 5;110(45):18250-5. doi: 10.1073/pnas.1314608110.

16.

Immunohistochemical evaluation of MYC expression in mantle cell lymphoma.

Oberley MJ, Rajguru SA, Zhang C, Kim K, Shaw GR, Grindle KM, Kahl BS, Kanugh C, Laffin J, Yang DT.

Histopathology. 2013 Oct;63(4):499-508. doi: 10.1111/his.12207.

17.

Cytarabine, Ki-67, and SOX11 in patients with mantle cell lymphoma receiving rituximab-containing autologous stem cell transplantation during first remission.

Chakhachiro ZI, Saliba RM, Okoroji GJ, Korbling M, Alousi AM, Betul O, Anderlini P, Ciurea SO, Popat U, Champlin R, Samuels BI, Medeiros LJ, Bueso-Ramos C, Khouri IF.

Cancer. 2013 Sep 15;119(18):3318-25. doi: 10.1002/cncr.28219.

18.

Initial therapy of mantle cell lymphoma.

Inwards DJ, Witzig TE.

Ther Adv Hematol. 2011 Dec;2(6):381-92. doi: 10.1177/2040620711412418.

19.

Molecular pathogenesis of mantle cell lymphoma.

Jares P, Colomer D, Campo E.

J Clin Invest. 2012 Oct;122(10):3416-23. doi: 10.1172/JCI61272. Review.

20.
Items per page

Supplemental Content

Support Center